Pfizer Beats Q3 Estimates, Raises 2026 Guidance and Names Cecile Guegan Permanent CFO

SentiSense · Published · Updated

Pfizer reported third-quarter 2026 adjusted EPS of $0.87, $0.14 above the $0.73 consensus, on revenue of $16.58 billion versus $15.87 billion expected...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis